论文部分内容阅读
目的 :探讨 p5 3和 mdm 2在骨巨细胞瘤 (GCT)的表达及与 GCT病理分级和复发的关系。方法 :应用 SP免疫组织化学方法检测 p5 3和 m dm 2在 5 2例 GCT(GCT按 Jaffe分级 : 级 15例、 级 2 5例、 级 12例 )中的表达。结果 :14例 p5 3表达阳性 ,阳性率 2 6 .9% ,18例 m dm 2表达呈阳性 ,阳性率 34.6 %。其阳性表达与病理分级均无显著性差异 (P值分别为 0 .6 99;0 .871)。 p5 3和 mdm 2在复发和无复发的病例中 ,阳性表达率分别为 46 .2 %、2 0 .5 %和 6 1.5 %、2 5 .6 %。两者同时阳性表达的有 7例 ,p5 3和 m dm 2同时过表达与 GCT复发有高度显著性差异 (P=0 .0 0 8)。结论 :p5 3和 m dm 2在 GCT中的表达与病理分级无关而与其复发有关。
Objective: To investigate the expression of p53 and mdm2 in giant cell tumor of bone (GCT) and its relationship with pathological grade and recurrence of GCT. Methods: SP immunohistochemistry was used to detect the expression of p53 and mdm2 in 52 cases of GCT (GCT by Jaffe grade: 15 cases, 25 cases, 12 cases). Results: The expression of p53 was positive in 14 cases, the positive rate was 26.9%. The expression of m dm 2 was positive in 18 cases, the positive rate was 34.6 %. There was no significant difference between the positive expression and pathological grade (P values were 0.69; 0.871). The positive expression rates of p53 and mdm2 in relapsed and relapsed cases were 46.2%, 20.5%, 61.5% and 25.6%, respectively. There were 7 cases of positive expression of both, and there was a highly significant difference between the overexpression of p53 and mdm2 and the recurrence of GCT (P=0.08). Conclusion : The expression of p53 and mdm2 in GCT has nothing to do with pathological grade but is related to its recurrence.